Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duvoglustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 6/20 | 1.00 |
| ▸ | GLA known ✓ | P06280 | 4/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 4/20 | 1.00 |
| ▸ | MGAM | O43451 | 4/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 3/20 | 1.00 |
| ▸ | SI | P14410 | 3/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | LCT | P09848 | 2/20 | 1.00 |
| ▸ | GBA3 | Q9H227 | 2/20 | 1.00 |
| ▸ | MAN2B1 | O00754 | 1/20 | 1.00 |
| ▸ | MAN2B2 | Q9Y2E5 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TREH | O43280 | 1/20 | 1.00 |
| ▸ | GANAB | Q14697 | 1/20 | 1.00 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duvoglustat SCHEMBL15896655 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL12636878 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL15896654 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL12017699 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Deoxymannojirimycin SCHEMBL3367857 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL24518227 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL4330678 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL2969 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL21104989 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 | |
| Duvoglustat SCHEMBL12909446 | 1.00 | GAA (1.00) | GAAFUCA1GLAMGAMGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3957320-B1 | AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE | AMICUS THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230220320-A1 | Method For Capturing And Purification Of Biologics | AMICUS THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20210393747-A1 | RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE | AMICUS THERAPEUTICS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CENTOGENE IP GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| US-11033538-B2 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | AMICUS THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3397273-B1 | AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE | AMICUS THERAPEUTICS INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10857212-B2 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | AMICUS THERAPEUTICS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10813921-B2 | Method to predict response to pharmacological chaperone treatment of diseases | AMICUS THERAPEUTICS, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10227577-B2 | Method for selection of high M6P recombinant proteins | AMICUS THERAPEUTICS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20190000818-A1 | Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2019-01-03 | — | — | US | disclosed |
| US-20180221357-A1 | METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES | AMICUS THERAPEUTICS, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20170335301-A1 | Method for Selection of High M6P Recombinant Proteins | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221357-A1 | METHOD FOR THE TREATMENT OF POMPE DISEASE USING 1-DEOXYNOJIRIMYCIN DERIVATIVES | GAA, MAN2B1, MAN1B1 | GAA 1/4885GLA 75/4885FUCA1 79/4885 |
| US-10227577-B2 | Method for selection of high M6P recombinant proteins | M6PR, MAN2B1, MTAP | GAA 20/4885GLA 439/4885FUCA1 233/4885 |
| US-11033538-B2 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | HSPA5, MAN2B1, GBA1 | GAA 5/4885GLA 328/4885FUCA1 439/4885 |
| US-20210228560-A1 | Combination of a Compound Having the Ability to Rearrange a Lysosomal Enzyme and Ambroxol and/or a Derivative of Ambroxol | CMA1, MAN2B1, GBA3 | GAA 13/4885GLA 45/4885FUCA1 113/4885 |
| US-20210393747-A1 | RECOMBINANT HUMAN ACID ALPHA-GLUCOSIDASE | GAA, MAN2B1, MAN2A1 | GAA 1/4885GLA 9/4885FUCA1 12/4885 |
| US-20170335301-A1 | Method for Selection of High M6P Recombinant Proteins | M6PR, MAN2B1, MTAP | GAA 20/4885GLA 439/4885FUCA1 233/4885 |
| US-20190000818-A1 | Method To Predict Response To Pharmacological Chaperone Treatment Of Diseases | MAN2B1, GAA, GBA1 | GAA 2/4885GLA 12/4885FUCA1 24/4885 |
| US-10857212-B2 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | GAA, MAN2B1, MANBA | GAA 1/4885GLA 10/4885FUCA1 24/4885 |
| US-10813921-B2 | Method to predict response to pharmacological chaperone treatment of diseases | MAN2B1, GAA, GBA1 | GAA 2/4885GLA 12/4885FUCA1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.